Physicians who have been through a medical practice split know too well that "breaking up is hard to do." As physicians, we invest a lot of time, energy, blood, sweat, and, tears into our professions and practices. Anything that threatens the stability, such as the dissolution of our practice, becomes a vital concern.
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.